Optimization of a Series of Mu Opioid Receptor (MOR) Agonists with High G Protein Signaling Bias
Open accessThe DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Abstract
While mu opioid receptor (MOR) agonists are especially effective as broad-spectrum pain relievers, it has been exceptionally difficult to achieve a clear separation of analgesia from many problematic side effects. Recently, many groups have sought MOR agonists that induce minimal βarrestin-mediated signaling because MOR agonist-treated βarrestin2 knockout mice were found to display enhanced antinociceptive effects with significantly less respiratory depression and tachyphylaxis. Substantial data now exists to support the premise that G protein signaling biased MOR agonists can be effective analgesic agents. We recently showed that, within a chemical series, the degree of bias correlates linearly with the magnitude of the respiratory safety index. Herein we describe the synthesis and optimization of piperidine benzimidazolone MOR agonists that together display a wide range of bias (G/βarr2). We identify structural features affecting potency and maximizing bias and show that many compounds have desirable properties, such as long half-lives and high brain penetration.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Taken together, the functional data reported here and elsewhere (Kennedy et al., 2018; Schmid et al., 2017) point towards a higher in vitro activity of chlorphine and brorphine (and iodorphine), compared to fluorphine and orphine, across two signaling pathways at MOR.”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Kennedy et al., 2018
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Limited pharmacological information is available in the scientific literature for orphine, fluorphine, and chlorphine (Janssen and Van der Eycken, 1968; Kennedy et al., 2018; Schmid et al., 2017); to date, there have been no studies on iodorphine.”
From Elucidating the harm potential of brorphine analogues as new synthetic opioids: Synthesis, in vitro, and in vivo characterization (2024) · cites this paper as Kennedy et al., 2018
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthes, H. W. D., Maldonado, R., Simonin, F., Valverde, O., Slowe, S., Kitchen, I., Befort, K., Dierich, A., Le Meur, M., Dollé, P., et al. (1996) · Nature · doi:10.1038/383819a0 · Cited by 1,722
Functional Selectivity and Classical Concepts of Quantitative Pharmacology
Urban, J. D., Clarke, W. P., von Zastrow, M., Nichols, D. E., Kobilka, B., Weinstein, H., Javitch, J. A., Roth, B. L., Christopoulos, A., Sexton, P. M., et al. (2007) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.106.104463 · Cited by 1,116
Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2
Bohn, L. M., Lefkowitz, R. J., Gainetdinov, R. R., Peppel, K., Caron, M. G., & Lin, F.-T. (1999) · Science · doi:10.1126/science.286.5449.2495 · Cited by 1,077
Self-citationOperational models of pharmacological agonism
Black, J. W., & Leff, P. (1983) · Proceedings of the Royal Society of London. Series B. Biological Sciences · doi:10.1098/rspb.1983.0093 · Cited by 951
Structure-based discovery of opioid analgesics with reduced side effects
Manglik, A., Lin, H., Aryal, D. K., McCorvy, J. D., Dengler, D., Corder, G., Levit, A., Kling, R. C., Bernat, V., Hübner, H., et al. (2016) · Nature · doi:10.1038/nature19112 · Cited by 944
μ-Opioid receptor desensitization by β-arrestin-2 determines morphine tolerance but not dependence
Bohn, L. M., Gainetdinov, R. R., Lin, F.-T., Lefkowitz, R. J., & Caron, M. G. (2000) · Nature · doi:10.1038/35047086 · Cited by 927
Self-citationOverdose deaths involving opioids, cocaine, and psychostimulants—United States, 2015–2016.
Seth, P., Scholl, L., Rudd, R. A., & Bacon, S. (2018) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6712a1 · Cited by 821
DeWire, S. M., Yamashita, D. S., Rominger, D. H., Liu, G., Cowan, C. L., Graczyk, T. M., Chen, X.-T., Pitis, P. M., Gotchev, D., Yuan, C., et al. (2013) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.201616 · Cited by 647
Morphine Side Effects in β-Arrestin 2 Knockout Mice
Raehal, K. M., Walker, J. K. L., & Bohn, L. M. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.087254 · Cited by 626
Self-citationBias factor and therapeutic window correlate to predict safer opioid analgesics
Schmid, C. L., Kennedy, N. M., Ross, N. C., Lovell, K. M., Yue, Z., Morgenweck, J., Cameron, M. D., Bannister, T. D., & Bohn, L. M. (2017) · Cell · doi:10.1016/j.cell.2017.10.035 · Cited by 567
Self-citation
Cited by
Faouzi, A., Varga, B. R., & Majumdar, S. (2020) · Molecules · doi:10.3390/molecules25184257 · Cited by 157
“3 G-protein 153 (GTPγS) 91 >10,000 (PathHunter) 12 NA [34]”
BackgroundInfluentialDARK Classics in Chemical Neuroscience: Etonitazene and Related Benzimidazoles
Ujváry, I., Christie, R., Evans-Brown, M., Gallegos, A., Jorge, R., de Morais, J., & Sedefov, R. (2021) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.1c00037 · Cited by 141
The Opioid Crisis and the Future of Addiction and Pain Therapeutics
Coussens, N. P., Sittampalam, G. S., Jonson, S. G., Hall, M. D., Gorby, H. E., Tamiz, A. P., McManus, O. B., Felder, C. C., & Rasmussen, K. (2019) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.119.259408 · Cited by 106
“Studies were presented of a m-opioid agonist series (Schmid et al., 2017; Kennedy et al., 2018) with favorable bias factors for guano-”
MethodBiased Agonism: Lessons from Studies of Opioid Receptor Agonists
Kelly, E., Conibear, A. E., & Henderson, G. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-052120-091058 · Cited by 107
Toward Directing Opioid Receptor Signaling to Refine Opioid Therapeutics
Grim, T. W., Acevedo-Canabal, A., & Bohn, L. M. (2020) · Biological Psychiatry · doi:10.1016/j.biopsych.2019.10.020 · Cited by 85
“4- to 100-fold preference as measured by either GTPγS binding or cAMP accumulation versus either βarrestin2 recruitment PathHunter® enzymatic complementation or recruitment of GFP-conjugated βarrestin2 (59, 60).”
BackgroundSelf-citationNovel Approaches, Drug Candidates, and Targets in Pain Drug Discovery
Obeng, S., Hiranita, T., León, F., McMahon, L. R., & McCurdy, C. R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00028 · Cited by 94
Reports of Adverse Events Associated with Use of Novel Psychoactive Substances, 2017–2020: A Review
Mohr, A. L. A., Logan, B. K., Fogarty, M. F., Krotulski, A. J., Papsun, D. M., Kacinko, S. L., Huestis, M. A., & Ropero-Miller, J. D. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkac023 · Cited by 68
The Rise and Fall of Isotonitazene and Brorphine: Two Recent Stars in the Synthetic Opioid Firmament
Vandeputte, M. M., Krotulski, A. J., Papsun, D. M., Logan, B. K., & Stove, C. P. (2022) · Journal of Analytical Toxicology · doi:10.1093/jat/bkab082 · Cited by 71
Low Intrinsic Efficacy Alone Cannot Explain the Improved Side Effect Profiles of New Opioid Agonists
Stahl, E. L., & Bohn, L. M. (2022) · Biochemistry · doi:10.1021/acs.biochem.1c00466 · Cited by 55
Self-citationOxidative Metabolism as a Modulator of Kratom’s Biological Actions
Chakraborty, S., Uprety, R., Slocum, S. T., Irie, T., Rouzic, V. L., Li, X., Wilson, L., Scouller, B., Alder, A. F., Kruegel, A. C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01111 · Cited by 63
Self-citationIn vitro functional characterization of a panel of non-fentanyl opioid new psychoactive substances
Vandeputte, M. M., Cannaert, A., & Stove, C. P. (2020) · Archives of Toxicology · doi:10.1007/s00204-020-02855-7 · Cited by 65
Fentanyl Family at the Mu-Opioid Receptor: Uniform Assessment of Binding and Computational Analysis
Lipiński, P. F. J., Kossoń, P., Matalińska, J., Roszkowski, P., Czarnocki, Z., Jarończyk, M., Misicka, A., Dobrowolski, J. C., & Sadlej, J. (2019) · Molecules · doi:10.3390/molecules24040740 · Cited by 61
“Although fentanyl itself or sufentanil are able to very effectively elicit unwanted (connected to adverse effects) β-arrestin recruitment [18], structurally close lie compounds with much higher preference for G-protein activation [19].”
BackgroundKhan, M. I. H., Sawyer, B. J., Akins, N. S., & Le, H. V. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114785 · Cited by 57
Papsun, D. M., Krotulski, A. J., & Logan, B. K. (2022) · American Journal of Forensic Medicine & Pathology · doi:10.1097/paf.0000000000000787 · Cited by 51
Khan, F., & Mehan, A. (2021) · Pharmacology Research & Perspectives · doi:10.1002/prp2.789 · Cited by 53
Barenholtz, E., Krotulski, A. J., Morris, P., Fitzgerald, N. D., Le, A., Papsun, D. M., Logan, B. K., Hahn, W. E., Goldberger, B. A., Cottler, L. B., et al. (2021) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2021.103393 · Cited by 47
Krotulski, A. J., Papsun, D. M., Noble, C., Kacinko, S. L., & Logan, B. K. (2021) · Journal of Forensic Sciences · doi:10.1111/1556-4029.14623 · Cited by 47
“, a series of substituted piperidine benzimidazolone analogues were synthetized as potential G protein signaling biased MOR agonists [24].”
BackgroundNeve, J. D., Barlow, T. M. A., Tourwé, D., Bihel, F. J. ‐., Simonin, F., & Ballet, S. (2021) · RSC Medicinal Chemistry · doi:10.1039/d1md00041a · Cited by 48
First Report on Brorphine: The Next Opioid on the Deadly New Psychoactive Substance Horizon?
Verougstraete, N., Vandeputte, M. M., Lyphout, C., Cannaert, A., Hulpia, F., Van Calenbergh, S., Verstraete, A. G., & Stove, C. (2021) · Journal of Analytical Toxicology · doi:10.1093/jat/bkaa094 · Cited by 44
“in the search for μ-opioid receptor (MOR) ligands biased toward G protein signaling (17).”
BackgroundMethodResultInfluentialVandeputte, M. M., Tsai, M.-H. M., Chen, L., Glatfelter, G. C., Walther, D., Stove, C. P., Shi, L., & Baumann, M. H. (2023) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2023.109939 · Cited by 39
Progress in the development of more effective and safer analgesics for pain management
Turnaturi, R., Chiechio, S., Salerno, L., Rescifina, A., Pittalà, V., Cantarella, G., Tomarchio, E., Parenti, C., & Pasquinucci, L. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.111701 · Cited by 34
Bonifazi, A., Battiti, F. O., Sanchez, J., Zaidi, S. A., Bow, E. W., Makarova, M., Cao, J., Shaik, A. B., Sulima, A., Rice, K. C., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00611 · Cited by 31
Xiong, J., Zhuang, T., Ma, Y., Xu, J., Ye, J., Ma, R., Zhang, S., Liu, X., Liu, B., Hao, C., et al. (2021) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2021.113879 · Cited by 26
Self-citationVandeputte, M. M., Vasudevan, L., & Stove, C. P. (2022) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2022.108161 · Cited by 23
Endogenous Opiates and Behavior: 2018
Bodnar, R. J. (2020) · Peptides · doi:10.1016/j.peptides.2020.170348 · Cited by 24
[ 11 C]Carbonyl Difluoride—a New and Highly Efficient [ 11 C]Carbonyl Group Transfer Agent
Jakobsson, J. E., Lu, S., Telu, S., & Pike, V. W. (2020) · Angewandte Chemie International Edition · doi:10.1002/anie.201915414 · Cited by 22
Grafinger, K. E., Wilde, M., Otte, L., & Auwärter, V. (2021) · Forensic Science International · doi:10.1016/j.forsciint.2021.110989 · Cited by 21
Pasquinucci, L., Turnaturi, R., Calò, G., Pappalardo, F., Ferrari, F., Russo, G. L., Arena, E., Montenegro, L., Chiechio, S., Prezzavento, O., et al. (2019) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2019.02.043 · Cited by 21
Massaly, N., Temp, J., Machelska, H., & Stein, C. (2020) · Pain · doi:10.1097/j.pain.0000000000001968 · Cited by 21
“A vast variety of strategies, including chemistry, genetics, and alteration of molecular and cellular pathways, is currently used by the pain research community to develop safer analgesics.(11,16,33,37) However, the translation from preclinical studies to the development of treatments applicable in patients remains Fi…”
BackgroundVandeputte, M. M., Bilel, S., Tirri, M., Corli, G., Bassi, M., Layle, N. K., Fantinati, A., Walther, D., Iula, D. M., Baumann, M. H., et al. (2024) · Neuropharmacology · doi:10.1016/j.neuropharm.2024.110113 · Cited by 19
Structure-guided design of partial agonists at an opioid receptor
Varga, B. R., Bernhard, S. M., Daibani, A. E., Zaidi, S. A., Lam, J. H., Aguilar, J. S., Appourchaux, K., Nazarova, A. L., Kouvelis, A., Shinouchi, R., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57734-5 · Cited by 23
Rahimi, S., Dadfar, B., Tavakolian, G., Rad, A. A., Shabkahi, A. R., & Siahposht-Khachaki, A. (2021) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2021.08.010 · Cited by 21
Jiang, X., Li, S., Zhang, H., & Wang, L. (2020) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2020.107405 · Cited by 19
Kasanami, Y., Ishikawa, C., Kino, T., Chonan, M., Toyooka, N., Takashima, Y., Iba, Y., Sekiguchi, F., Tsubota, M., Ohkubo, T., et al. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114716 · Cited by 17
Deng, M., Zhang, Z., Xing, M., Liang, X., Li, Z., Wu, J., Jiang, S., Weng, Y., Guo, Q., & Zou, W. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2021.108938 · Cited by 17
The G Protein Signal-Biased Compound TRV130; Structures, Its Site of Action and Clinical Studies
Miyano, K., Manabe, S., Komatsu, A., Fujii, Y., Mizobuchi, Y., Uezono, E., Ohshima, K., Nonaka, M., Kuroda, Y., Narita, M., et al. (2020) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026620999201027224229 · Cited by 16
Plasma drug screening using paper spray mass spectrometry with integrated solid phase extraction
Zimmerman, H., Ren, G., Dowling, S., Warren, C., Rusyniak, D. E., Avera, R., & Manicke, N. E. (2024) · Drug Testing and Analysis · doi:10.1002/dta.3687 · Cited by 13
“76 that appeared in the US drug market in the second half of 2020 77 , often in combination with flualprazolam and fentanyl 78 .”
Trojniak, A. E., Dang, V. Q., Czekner, K. M., Russo, R. J., Mather, L. M., Stahl, E. L., Cameron, M. D., Bohn, L., & Aubé, J. (2024) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2024.116627 · Cited by 13
Self-citationFlorou, D., Vlachou, T., Sakkas, V. A., & Boumba, V. A. (2022) · Journal of Xenobiotics · doi:10.3390/jox12040025 · Cited by 11
Noncoding RNAs: Novel Targets for Opioid Tolerance
Deng, M., & Zou, W. (2022) · Current Neuropharmacology · doi:10.2174/1570159x21666221129122932 · Cited by 11
Ma, X., Chen, R., Huang, M., Wang, W., Luo, L., Kim, D. K., Jiang, W., & Xu, T. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173118 · Cited by 14
Vandeputte, M. M., Walton, S. E., Shuda, S. A., Papsun, D. M., Krotulski, A. J., & Stove, C. P. (2023) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-023-04722-7 · Cited by 10
A Bibliometric and Visual Analysis of Oliceridine Research (2013–2024)
Song, C., Huang, X., Chen, N., Song, Q., & Qiu, Y. (2025) · Drug Design Development and Therapy · doi:10.2147/dddt.s497186 · Cited by 7
“33 The therapeutic window of oliceridine in specific patient populations is also the focus of current research.”
Wu, D., Zeng, X., Zhao, Y., Qin, M., & Gong, P. (2024) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2024.117725 · Cited by 7
Huang, H., Li, X., Xie, P., Li, X., Xu, X., Qian, Y., Yuan, C., Meng, X., Chai, J., Chen, J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c00722 · Cited by 7
Miao, Z., Zhong, Y., Gan, Y., Fu, K., Liu, W., Cao, Z., Zhao, T., Li, Z., Hai, A., Peng, Y., et al. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01637 · Cited by 7
Dugues, P., Robin, T., Bellouard, M., Chenorhokian, S., Triguel, M., Pfau, G., Feng, C., Cherki, S., Herbette, G., Alvarez, J. C., et al. (2026) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2025-1428 · Cited by 6
“Structural comparison between cychlorphine and chlorphine for e.g. suggests that cychlorphine is likely to act as a high-potency MOR agonist, with associated risks of profound respiratory depression, sedation, and a narrow therapeutic window [26].”
[11C]Carbonyl Difluoride—a New and Highly Efficient [11C]Carbonyl Group Transfer Agent
Jakobsson, J. E., Lu, S., Telu, S., & Pike, V. W. (2020) · Angewandte Chemie · doi:10.1002/ange.201915414 · Cited by 6
Brorphine and Its Analogues: Pharmacology, Toxicology, and Biomonitoring
Marchei, E., Graziano, S., Pichini, S., & Farré, M. (2026) · Therapeutic Drug Monitoring · doi:10.1097/ftd.0000000000001446 · Cited by 5
New Synthetic Opioids: What Do We Know About the Mutagenicity of Brorphine and Its Analogues?
Lenzi, M., Gasperini, S., Bilel, S., Corli, G., Rombolà, F., Hrelia, P., & Marti, M. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26115084 · Cited by 5
“In assays of agonist activity (G protein activation) at the MOR, Brorphine has proven to be a high-efficacy agonist, approximately 13 times more potent than morphine [3].”
Ferreira, C. F., Antunes, A. M. M., Gaspar, H., & Caldeira, M. J. (2025) · Forensic Chemistry · doi:10.1016/j.forc.2025.100696 · Cited by 5
In Vitro Effects of Ligand Bias on Primate Mu Opioid Receptor Downstream Signaling
Zhang, X., Hutchins, S., Blough, B. E., & Vallender, E. J. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21113999 · Cited by 5
“G-protein signaling has previously been suggested to play a crucial role in the analgesic properties of MOR ligands, and a bias towards these signaling pathways has been suggested to reflect an improved therapeutic window [27,43,44].”
BackgroundWill biased ligands be the opioids of the future?
Ballantyne, J. C., & Chavkin, C. (2020) · Pain · doi:10.1097/j.pain.0000000000001913 · Cited by 6
Encoding mu-opioid receptor biased agonism with interaction fingerprints
Hernández-Alvarado, R. B., Madariaga‐Mazón, A., Cosme-Vela, F., Marmolejo-Valencia, A. F., Nefzi, A., & Martínez‐Mayorga, K. (2021) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-021-00422-5 · Cited by 5
The methodology for preparing domperidone: strategies, routes and reaction processes
Yu, L., Shao, R., Guo, Q., Hong, H., & Ning, Z. H. (2022) · RSC Advances · doi:10.1039/d2ra03777g · Cited by 4
Tran, L. T., Freeman, K. T., Lunzer, M. M., Portoghese, P. S., & Haskell‐Luevano, C. (2024) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.4c00604 · Cited by 4
Krüll, J., Fehler, S. K., Hofmann, L. E., Nebel, N., Maschauer, S., Prante, O., Gmeiner, P., Lanig, H., Hübner, H., & Heinrich, M. R. (2020) · ChemMedChem · doi:10.1002/cmdc.202000180 · Cited by 5
Hernandez, D. E., Luo, D., Prisinzano, T. E., Negus, S. S., Nassehi, N., Selley, D. E., Shah, P., Kato, R., Xu, X., Talarico, C., et al. (2025) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.5c00211 · Cited by 2
Rullo, L., Losapio, L. M., Morosini, C., Candeletti, S., & Romualdi, P. (2022) · doi:10.36118/pharmadvances.2022.29 · Cited by 1
“idine as important structural features for bias (19, 62).”
BackgroundMapping of the Akt and Beta-arrestin Interface for Drug Development
St-Pierre, A. (2019) · TSpace (University of Toronto) · Cited by 1
Norman, C., Ottosson, N. E., Rosengren-Holmberg, J. P., Norlund, M., Homan, E. J., Wikström, M., Kronstrand, R., Persson, M., & Gréen, H. (2026) · Research Square · doi:10.21203/rs.3.rs-10344997/v1 · Cited by 1
Biased Agonism at µ-Opioid Receptor - The Quest for Safer Analgesics
Line, F. A. (2019) · NORA - Norwegian Open Research Archives
Wong, B. A. (2020) · ResearchWorks at the University of Washington (University of Washington)
Helfer, die in die Hölle führen können: Von Opium zu Fentanyl
Strey, K. (2025) · Chemie in unserer Zeit · doi:10.1002/ciuz.202400019
Advances in GPCR therapeutics for the treatment of central nervous system diseases
Andreotti, D., Iliopoulos‐Tsoutsouvas, C., Hall, A., Makriyannis, A., & Rossi, T. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-29808-0.00053-4
Discovery of Highly Potent G Protein-Biased Bisamide Kappa Opioid Receptor Agonists
Taylor, K. S., Czekner, K. M., Harland, A. A., Ma, H., Dang, V. Q., Koehn, K. R. K., Frankowski, K. J., Stahl, E. L., Cameron, M. D., Bohn, L., et al. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6c01108
Self-citationVardanyan, R., & Vardanyan, G. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-33869-4.00021-1
Underwood, O. (2024) · Nottingham ePrints (University of Nottingham)
CURRENT AND EMERGING PHARMACOTHERAPIES IN OPIOID USE DISORDER: A NARRATIVE REVIEW
Mubashir Raza, J. K. S. (2026) · Review journal of neurological & medical sciences review. · doi:10.5281/zenodo.18781137
Molecular recognition of piperidine derivatives as MOR modulators
Naseem, H., Mushtaq, N., & Ul‐Haq, Z. (2026) · Letters in Drug Design & Discovery · doi:10.1016/j.lddd.2026.100499
Jahan, K., Bonifazi, A., Sanchez, J., Saab, E., Jackson, S. N., Tressler, E. H., Cymek, K. S., Vendruscolo, J. C. M., Bi, G.-H., Maras, M., et al. (2026) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.6c00333
Bracaglia, I., Chiodo, L., Montesano, C., Bilel, S., Bassi, M., Cocita, N., Rosa, F. D., Gregori, A., Marti, M., Marini, F., et al. (2026) · Metabolites · doi:10.3390/metabo16100770
“Several studies have further highlighted significant variations in µ -opioid receptor (MOR) agonist selectivity among brorphine analogues [18].”
BindingDB Entry 50018514: Oxidative Metabolism as a Modulator of Kratom's Biological Actions.
BindingDB (2024) · UC San Diego · doi:10.7270/q2k64p8b
BindingDB Entry 50020556: A Novel Bifunctional μOR Agonist and σ
BindingDB (2024) · UC San Diego · doi:10.7270/q2ng4w4d
BindingDB Entry 50015301: Novel Dual-Target μ-Opioid Receptor and Dopamine D
BindingDB (2023) · UC San Diego · doi:10.7270/q2n301v5
BindingDB Entry 50014953: Optimization of bifunctional piperidinamide derivatives as σ
BindingDB (2023) · UC San Diego · doi:10.7270/q26w9fzs
BindingDB (2024) · UC San Diego · doi:10.7270/q2154n75
BindingDB (2021) · UC San Diego · doi:10.7270/q2668hn9
Metadata
- Authors
- Kennedy, N. M., Schmid, C. L., Ross, N. C., Lovell, K. M., Yue, Z., Chen, Y. T., Cameron, M. D., Bohn, L. M., & Bannister, T. D.
- Affiliations
- Scripps Research Institute (US)
- Corresponding author
- Bohn, Laura M.
- Bannister, Thomas D.
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2018-09-10
- Volume
- 61
- Issue
- 19
- Pages
- 8895-8907
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- PMC
- PMC6386185
- OpenAlex
- W2891113839
- Cited by
- 71
- References
- 32
- Citations by year
- 2026: 5 · 2025: 10 · 2024: 8 · 2023: 3 · 2022: 11 · 2021: 14 · 2020: 14 · 2019: 6
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institute on Drug Abuse (R01DA038694, R01DA033073)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Receptor Mechanisms and Signaling
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuropeptides and Animal Physiology
- Health Sciences › Medicine › Anesthesiology and Pain Medicine › Pain Management and Opioid Use
- Keywords
- mu-opioid receptor agonists, β-arrestin2, benzimidazolone derivatives, piperidine derivatives, analgesia, respiratory depression, tachyphylaxis, structure-activity optimization, brain penetration, opioid side effects
- MeSH terms
- beta-Arrestins, Analgesics, Opioid, Animals, Blood-Brain Barrier, Humans, Male, Mice, Inbred C57BL, Microsomes, Liver, Protein Conformation, Structure-Activity Relationship, Receptors, Opioid, mu, GTP-Binding Proteins, Mice, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.